Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
April 25, 2018
ARMO BioSciences Announces Poster Presentations of Pegilodecakin (AM0010) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (ARMO), a late-stage immuno-oncology company, today announced three abstracts on pegilodecakin (AM0010), a ...
April 25, 2018
FDA Determines that Afrezza REMS Communication Plan Has Met Goals and REMS No Longer Necessary
WESTLAKE VILLAGE, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), focused on the development and commercialization of inhaled therapeutic products for patients with ...
April 25, 2018
Aptose Announces Appointment of Caroline M. Loewy to Board of Directors
SAN DIEGO and TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (APTO) (APS.TO), a clinical-stage company developing highly differentiated therapeutics targeting the underlying ...
April 25, 2018
Zogenix Announces Presentation of New Efficacy and Safety Data from its First Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
EMERYVILLE, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
April 25, 2018
PolarityTE, Inc. Regains Compliance With NASDAQ Independent Director Requirement
SALT LAKE CITY, April 25, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (COOL) today announced it has received formal notification from the Listing Qualifications Department of ...
April 25, 2018
DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis
CUPERTINO, Calif., April 25, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 ...
April 25, 2018
Achaogen to Host Conference Call and Webcast of First Quarter 2018 Financial Results on May 4, 2018
SOUTH SAN FRANCISCO, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative ...
April 25, 2018
Theravance Biopharma Highlights Approval of Expanded Indication in the US for Once-Daily Trelegy Ellipta for Treatment of COPD Patients
DUBLIN, April 25, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today highlighted that the US Food and Drug Administration (FDA) has approved an expanded ...
April 25, 2018
Onxeo S.A.: Combined General Meeting on May 16, 2018
PARIS--(BUSINESS WIRE)-- Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against ...
April 24, 2018
Onxeo Announces Initiation of DRIIV Phase I Clinical Trial of AsiDNA™ for Treatment of Advanced Solid Tumor
PARIS--(BUSINESS WIRE)--Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, notably against rare ...
April 24, 2018
Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Second Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it will host a webcast and conference call on May 8, 2018, at 4:30 p.m. EDT ...
April 24, 2018
Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich’s Ataxia and Other Severe Neurological Diseases
IRVING, Texas, April 24, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced new preclinical data demonstrating ...
April 24, 2018
DURECT Corporation Invites You to Join its First Quarter 2018 Earnings Conference Call
CUPERTINO, Calif., April 24, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's(DRRX) first quarter 2018 financial results press release, you are invited to listen to a ...
April 24, 2018
OSE Immunotherapeutics Receives the EuroNext Tech40 Label
NANTES, France, April 23, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN:FR0012127173) (Mnémo:OSE) has received the EuroNext Tech40 Label and is thus admitted to the “Tech40” ...
April 24, 2018
Biom’up Has Trained 200 Surgeons in its International KOL-Led Program Ahead of HEMOBLAST Bellows™ Launch
NEW YORK and SAINT-PRIEST, France, April 24, 2018 (GLOBE NEWSWIRE) -- Biom'up (BUP.PA), a specialist in surgical hemostasis, today announced that its intensive training program ...
April 24, 2018
Lysogene Signs Partnership Agreement with Dr. Hervé Moine, Researcher at the IGBMC(1) and the SATT(2) Conectus Alsace, in the Fragile X Syndrome
CAMBRIDGE, Mass. and PARIS, April 24, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a leading biopharmaceutical company pioneering gene therapy technologies to treat central ...
April 24, 2018
PureTech Health Appoints Joep Muijrers as Chief Financial Officer
BOSTON--(BUSINESS WIRE)--PureTech Health plc (PRTC.L) (“PureTech Health” or the “Company”), an advanced, clinical-stage biopharmaceutical company, is pleased to announce today the appointment of Joep Muijrers, ...
April 24, 2018
Aptose to Present at the Bloom Burton & Co. Healthcare Investor Conference 2018
SAN DIEGO and TORONTO, April 24, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (APTO) (APS.TO), a clinical-stage company developing highly differentiated ...
April 24, 2018
Intec Pharma Presented Phase 1 PK and Safety Data From Accordion Pill Carbidopa/Levodopa at American Academy of Neurology Annual Meeting
JERUSALEM, April 24, 2018 /PRNewswire/ -- Intec Pharma LTD (NASDAQ, TASE: NTEC) ("Intec" or "the Company") today announces that data collected from two Phase 1 studies ...
April 24, 2018
CytoSorbents Enrolls First Patient into Pivotal U.S. REFRESH 2-AKI Trial Using CytoSorb® During Complex Cardiac Surgery
MONMOUTH JUNCTION, N.J., April 24, 2018 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation ...
Page 48 of 117